FLUDARABINE (FLUDARA)

Course overview

Fludarabine is U.S. FDA-approved to treat refractory or relapsed B-cell chronic lymphocytic leukemia (CLL) in adults. It must be used cautiously in older patients, and in patients with preexisting bone marrow suppression, large tumor burden, fever or documented infection, preexisting CNS disorders, or mild/moderate renal impairment. This continuing education module is designed to give the reader/learner an increased understanding of fludarabine. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.